Read by QxMD icon Read


Lara Baticic Pucar, Ester Pernjak Pugel, Dijana Detel, Jadranka Varljen
Dipeptidyl peptidase IV (DPP IV/CD26) is a widely distributed multifunctional protein that plays a significant role in different physiological as well as pathological processes having a broad spectrum of bioactive substrates and immunomodulative properties. It has potential influence on different processes crucial for wound healing, including cell adhesion, migration, apoptosis and extracellular matrix degradation. However, despite its known enzymatic and immunomodulative functions, limited data characterize the role of DPP IV/CD26 in cutaneous wound healing mechanisms...
November 21, 2016: Wound Repair and Regeneration
Nadine M P Daan, Maria P H Koster, Marlieke A de Wilde, Gerdien W Dalmeijer, Annemieke M V Evelein, Bart C J M Fauser, Wilco de Jager
OBJECTIVE: To study metabolic/inflammatory biomarker risk profiles in women with PCOS and PCOS offspring. DESIGN: Cross-sectional comparison of serum biomarkers. SETTING: University Medical Center Utrecht. PATIENTS: Hyperandrogenic PCOS women (HA-PCOS, n = 34), normoandrogenic PCOS women (NA-PCOS, n = 34), non-PCOS reference population (n = 32), PCOS offspring (n = 14, age 6-8 years), and a paedriatic reference population (n = 30)...
2016: PloS One
Jaeseong Oh, Andrew HyoungJin Kim, SeungHwan Lee, Hyunjeong Cho, Yon Su Kim, Mi Young Bahng, Seo Hyun Yoon, Joo-Youn Cho, In-Jin Jang, Kyung-Sang Yu
Evogliptin is a novel potent and selective dipeptidyl peptidase-IV (DPP-IV) inhibitor. This study aimed to evaluate the pharmacokinetic and pharmacodynamic characteristics of evogliptin in renal impairment (RI) subjects. An open-label, parallel-group clinical study was conducted on mild, moderate, and severe RI subjects and matched normal renal function (NRF) subjects. A single oral 5 mg dose of evogliptin was administered and serial blood and urine samples were obtained to assess the pharmacokinetic and pharmacodynamic characteristics of evogliptin...
October 20, 2016: Diabetes, Obesity & Metabolism
Rehab Mohmed El-Gharbawy, Ashraf Mahmoud Emara, Sally El-Sayed Abu-Risha
The aim of this study was to use Zinc oxide nanoparticles and a standard antidiabetic drug to restore the function and structure of beta cells in a rat model of Type-2 diabetes and compare the effects of a DPP-IV inhibitor with or without zinc oxide nanoparticles (ZnONPs) using a model of type 2 diabetes (rats fed a high fat diet that was treated with a low dose of streptozotocin). Ninety male Wistar rats were randomly divided into three groups 10days after the induction of diabetes: group I: non-diabetic animals that received only the chow diet plus 2ml of 0...
October 7, 2016: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
Adriana C Neves, Pádraigín A Harnedy, Martina B O'Keeffe, Richard J FitzGerald
The pH shift method was utilised for the recovery of proteins from salmon trimmings (ST), yielding 93% (w/w) protein. ST protein (STP) hydrolysates were generated with different enzyme preparations. STP incubated with Corolase PP for 1h (STP-C1) had the most potent angiotensin converting enzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory and oxygen radical absorbance capacity (ORAC) activities. Analysis of fractions of STP-C1 using UPLC-MS/MS identified sixteen peptides/amino acids. Tyr-Pro had the highest ACE inhibitory activity (ACE IC50=5...
March 1, 2017: Food Chemistry
Luis Mojica, Diego A Luna-Vital, Elvira González de Mejía
BACKGROUND: Diabetes and hypertension are diseases affecting a high proportion of the world population; the use of food-based products such as common bean peptides may contribute to reduce the risk of complications associated to chronic diseases. The aim was to produce and characterize peptides from common bean protein isolates and evaluate their potential to inhibit markers of type-2 diabetes, hypertension and oxidative stress. RESULTS: Mexican black and Brazilian Carioca bean isolated proteins were characterized after pepsin/pancreatin digestion...
September 24, 2016: Journal of the Science of Food and Agriculture
Katarzyna Grzela, Malgorzata Litwiniuk, Alicja Krejner, Wioletta Zagorska, Tomasz Grzela
Asthma progression is associated with airway remodeling and neo-vascularization. However, role of angiogenesis in these changes remains unclear and available data still incomplete. In this pilot study we verify usefulness of proteome profiler assay in screening of angiogenesis-related factors in exhaled breath condensates (EBC) collected from children with asthma. EBC samples from patients with mild or severe asthma and healthy controls were tested using protein array. In EBC samples from patients with severe asthma we have found large quantities of several angiogenesis regulators, including thrombospondin (TSP)-1, angiogenin, dipeptidyl peptidase (DPP) IV, matrix metalloproteinase (MMP)-9 and its inhibitor TIMP-1...
September 2016: Respiratory Medicine
Zohreh Amini, Mohammad Hossein Fatemi, Sajjad Gharaghani
In this study, the dipeptidyl peptidase-IV (DPP-IV) inhibition activities of a series of novel aminomethyl-piperidones were investigated by molecular docking studies and modeled by quantitative structure-activity relationship (QSAR) methodology. Molecular docking studies were used to find the best conformations of the studied molecules in the active site of DPP-IV protein. Then the best docking-derived conformation for each molecule was applied for calculating the molecular descriptors. Multiple linear regression (MLR) and Levenberg-Marquardt artificial neural network (LM-ANN) were conducted on descriptors derived by docking...
August 20, 2016: Computational Biology and Chemistry
Gang Li, Yi Huan, Baokun Yuan, Jin Wang, Qian Jiang, Ziyun Lin, Zhufang Shen, Haihong Huang
A series of xanthine derivatives as potent dual ligands targeting DPP-IV and GPR119 was discovered through an approach of the merged pharmacophores of GPR119 agonists and DPP-IV inhibitor linagliptin. Systematic optimization of general structure 5 led to the identification of compound 20i with selective DPP-IV inhibition, good GPR119 agonism activity and favorable metabolic stability. Docking study was performed to elucidate the potent DPP-IV inhibition of 20i. Compound 20i may serve as a tool compound for further design of anti-diabetic drugs targeting both DPP-IV and GPR119...
August 13, 2016: European Journal of Medicinal Chemistry
Lingqian Du, Ruijuan Feng, Shaohua Ge
OBJECTIVES: Stromal cell-derived factor-1α (SDF-1α) plays an important role in tissue regeneration in various tissues including the periodontium. A potential limitation for its use derives from its sensitivity to cleavage by dipeptidyl peptidase-IV (DPP-IV). Parathyroid hormone (PTH) reduces enzymatic activity of DPP-IV and is suggested to be a promising agent for periodontal tissue repair. The purpose of this study was to provide insight into how SDF-1α and intermittent PTH treatment might affect proliferation, migration and osteogenic differentiation of human periodontal ligament stem cells (PDLSCs) in vitro...
October 2016: Cell Proliferation
Toshiharu Nagatsu
Prolyl oligopeptidase (also named prolyl endopeptidase; PREP) hydrolyzes the Pro-Xaa bonds of biologically active oligopeptides on their carboxyl side. In 1987, we detected PREP activity in human cerebrospinal fluid (CSF) using highly sensitive liquid chromatography-fluorometry with succinyl-Gly-Pro-4-methyl-coumarin amide as a new synthetic substrate, and found a marked decrease in its activity in the cerebrospinal fluid (CSF) from patients with Parkinson's disease (PD) as compared with its level in control patients without neurological diseases...
August 8, 2016: Journal of Neural Transmission
Yin-Shiou Lin, Chuan-Hsiao Han, Shyr-Yi Lin, Wen-Chi Hou
RRDY, RL, and DPF were the top 3 of 21 peptides for inhibitions against dipeptidyl peptidase-IV (DPP-IV) from the pepsin hydrolysis of yam dioscorin in silico and were further investigated in a proof-of-concept study in normal ICR mice for regulating glucose metabolism by the oral glucose tolerance test (OGTT). The sample or sitagliptin (positive control) was orally administered by a feeding gauge; 30 min later, the glucose loads (2.5 g/kg) were performed. RRDY, yam dioscorin, or sitagliptin preload, but not DPF, lowered the area under the curve (AUC0-120) of blood glucose and DPP-IV activity and elevated the AUC0-120 of blood insulin, which showed significant differences compared to control (P < 0...
August 24, 2016: Journal of Agricultural and Food Chemistry
Eisuke Kato, Yuta Uenishi, Yosuke Inagaki, Mihoko Kurokawa, Jun Kawabata
Dipeptidyl peptidase-IV (DPP-IV) is a protease responsible for the degradation of the incretin hormone. A number of DPP-IV inhibitors have been approved for use in the treatment of type 2 diabetes. While these inhibitors are effective for this treatment, methods for the prevention of this disease are also required as diabetes patient numbers are currently increasing rapidly worldwide. We screened the DPP-IV inhibitory activities of edible plant extracts with the intention of using these extracts in a functional food supplement for the prevention of diabetes...
August 1, 2016: Bioscience, Biotechnology, and Biochemistry
Leslie E Neidert, Katherine S Wainright, Chen Zheng, Jeganathan Ramesh Babu, Heidi A Kluess
AIM: Based on its regulatory action on glucagon-like peptide 1, dipeptidyl peptidase IV (DPP-IV) has increasingly been linked to Type 2 diabetes. However, there is no evidence as to how this normal modulatory enzyme leads to pathology. It is thought that DPP-IV is affected by the development of obesity, which is a common precursor to Type 2 diabetes. Little is known about the relationship between DPP-IV activity in plasma and specific body composition measures. MAIN METHODS: In the current study, plasma DPP-IV activity and body composition measures were collected from 111 healthy subjects between the ages of 19 and 70 years old for analysis...
April 2016: Heliyon
Alice B Nongonierma, Solène Le Maux, Joël Hamayon, Richard J FitzGerald
Bovine α-lactalbumin (α-La) contains numerous dipeptidyl peptidase IV (DPP-IV) inhibitory peptide sequences within its primary structure. In silico analysis indicated that the targeted hydrolysis of α-La with elastase should release DPP-IV inhibitory peptides. An α-La isolate was hydrolysed with elastase under different conditions using an experimental design approach incorporating 3 factors (temperature, pH and enzyme to substrate ratio (E : S) ratio) at 2 levels. The hydrolyzate generated at pH 8...
August 10, 2016: Food & Function
Lucie Sromova, Petr Busek, Helena Posova, Jana Potockova, Pavel Skrha, Michal Andel, Aleksi Sedo
AIM: To assess intraindividually the effects of DPP-IV inhibition on the subpopulations of immune cells in type 2 diabetes mellitus (DM2) patients during the course of treatment with sitagliptin. METHODS: In this open label non-randomized observational study with a control group DM2 patients were examined before the initiation of the DPP-IV inhibitor administration (sitagliptin 100mg once daily) and then after 4weeks and 12months. Inhibition of the blood plasma DPP-IV enzymatic activity was determined by a chromogenic assay, the immunophenotyping of the blood cell subpopulations was performed using flow cytometry and blood plasma cytokine concentrations were quantified using an array-based multiplex ELISA...
August 2016: Diabetes Research and Clinical Practice
Trevor Hardigan, Abdul Yasir, Mohammed Abdelsaid, Maha Coucha, Sally El-Shaffey, Weiguo Li, Maribeth H Johnson, Adviye Ergul
The antihyperglycemic agent linagliptin, a dipeptidyl peptidase-4 (DPP-IV) inhibitor, has been shown to reduce inflammation and improve endothelial cell function. In this study, we hypothesized that DPP-IV inhibition with linagliptin would improve impaired cerebral perfusion in diabetic rats, as well as improve insulin-induced cerebrovascular relaxation and reverse pathological cerebrovascular remodeling. We further postulated that these changes would lead to a subsequent improvement of cognitive function. Male Type-2 diabetic and nondiabetic Goto-Kakizaki rats were treated with linagliptin for 4 wk, and blood glucose and DPP-IV plasma levels were assessed...
September 1, 2016: American Journal of Physiology. Regulatory, Integrative and Comparative Physiology
Leslie E Neidert, C Brooks Mobley, Wesley C Kephart, Michael D Roberts, Heidi A Kluess
Dipeptidyl-peptidase IV (DPP-IV) is an enzyme with numerous roles within the body, mostly related to regulating energy metabolism. DPP-IV is also a myokine, but the stimulus for its release is poorly understood. We investigated the transcription and release of DPP-IV from skeletal muscle in a three-part study using C2C12 myotube cultures, an acute rat exercise and postexercise feeding model, and human feeding or human exercise models. When myotubes were presented with leucine only, hydrolyzed whey protein, or chemicals that cause exercise-related signaling to occur in cell culture, all caused an increase in the mRNA expression of DPP-IV (1...
June 2016: Physiological Reports
Petr Busek, Zdislava Vanickova, Petr Hrabal, Marek Brabec, Premysl Fric, Miroslav Zavoral, Jan Skrha, Klara Kmochova, Martin Laclav, Bohus Bunganic, Koen Augustyns, Pieter Van Der Veken, Aleksi Sedo
BACKGROUND/OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) is frequently heralded by an impairment of glucose homeostasis. Dipeptidyl peptidase-IV (DPP-IV) and fibroblast activation protein alpha (FAP) are aminopeptidases that regulate several bioactive peptides involved in glucoregulation, and are frequently dysregulated in cancer. The present study analyzes blood plasma levels and the quantity and localization of DPP-IV and FAP in PDAC tissues. METHODS: DPP-IV and FAP concentration and enzymatic activity were evaluated in the plasma from 93 PDAC, 39 type 2 diabetes mellitus (T2DM) and 29 control subjects, and in matched paired non-tumorous and tumor tissues from 48 PDAC patients...
September 2016: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
Alice B Nongonierma, Solène Le Maux, Claire Esteveny, Richard J FitzGerald
BACKGROUND: Hydrolysis parameters affecting the release of dipeptidyl peptidase IV (DPP-IV) inhibitory and antioxidant peptides from milk proteins have not been extensively studied. Therefore, a multifactorial (i.e., pH, temperature and hydrolysis time) composite design was used to optimise the release of bioactive peptides (BAPs) with DPP-IV inhibitory and antioxidant (oxygen radical absorbance capacity - ORAC) properties from sodium caseinate (NaCN). RESULTS: Fifteen NaCN hydrolysates (H1-H15) were generated with Protamex(TM) , a bacillus proteinase activity...
June 8, 2016: Journal of the Science of Food and Agriculture
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"